

Effect of Crizanlizumab, a P-selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial

Supplemental Appendix

Page 2. Supplemental Table S1. Data and Safety Monitoring Board (DSMB)

Page 3. Supplemental Table S2. Inclusion and Exclusion Criteria

Page 4. Supplemental Table S3. Sources of commercially available immunoassays used in the study.

Page 5. Supplemental Table S4. WHO Clinical Progression Scale

Supplemental Table S1. Data and Safety Monitoring Board (DSMB)

Mark Creager, MD (Chair of DSMB), Anna Gundlach Huber Professor in Medicine, Geisel School of Medicine at Dartmouth, Director of the Heart and Vascular Center at Dartmouth-Hitchcock Medical Center, Dartmouth, NH

Paul E. Sax, MD, Professor of Medicine, Clinical Director, Infectious Disease Clinic, Harvard Medical School, Boston, MA

Julie Kanter, MD, Associate Professor of Medicine; Co-Director of the Comprehensive Sickle Cell Center, University of Alabama at Birmingham, AL

Supplemental Table S2. Inclusion and Exclusion Criteria

Inclusion criteria	<ol style="list-style-type: none">1. Willing to provide written informed consent.2. Willing to comply with all study procedures and be available for the duration of the study3. Male or female ≥ 18 years of age4. SARS-CoV-2 infection (COVID-19) within the past 10 d documented by laboratory test (NAT or RT-PCR)5. Currently hospitalized6. Symptoms of acute respiratory infection (at least one of the following: cough, fever $> 37.5^{\circ}\text{C}$, dyspnea, sore throat, anosmia) within past 10 days7. Radiographic evidence of pulmonary infiltrates8. Requiring supplemental oxygen or the peripheral capillary oxygenation saturation (SpO_2) $< 94\%$ on room air at screening.9. Elevated D-Dimer > 0.49 mg/L10. Negative pregnancy test for females of childbearing potential
Key Exclusion criteria	<ol style="list-style-type: none">1. Use of home oxygen at baseline2. Current use of mechanical ventilation3. Inability to provide informed consent4. Do Not Intubate status5. Prisoner or incarcerated status6. Pregnant or nursing (lactating) women.7. Participation in other interventional drug trials for COVID-19 (emergency use or unblinded use of convalescent plasma is permitted).8. INR > 3 or aPTT > 60

Supplemental Table S3. Sources of commercially available immunoassays used in the study.

Supplier	Analyte
R&D Systems (Minneapolis, MN)	Soluble P-selectin
	IL-6
	TNFalpha
Abcam (Cambridge, MA)	VWF
	Fibrinogen
	Thrombin-antithrombin complex
Lifespan Biosciences (Seattle, WA)	NT-proBNP
	Factor VIII
	Prothrombin fragment 1.2
	Plasmin-antiplasmin complex
Roche Diagnostics (Indianapolis, IN)	Troponin T
Meso Scale Diagnostics (Rockville, MD)	CCL2
	CCL3
	CCL4
	CCL13
	CCL22
	CCL24
	CCL26
	CXCL10
	IL-2
	IL-4
	IL-8
	IL-10
	IL-13
	Serum amyloid A
	VCAM-1
	ICAM-1

Supplemental Table S4. WHO Clinical Progression Scale. WHO clinical scale for severity of COVID-19.

Score	Descriptor
0	Uninfected; no viral RNA detected
1	Asymptomatic; viral RNA detected
2	Symptomatic; independent
3	Symptomatic; assistance needed
4	Hospitalized; no oxygen therapy
5	Hospitalized; oxygen by mask or nasal prongs
6	Hospitalized; oxygen by NIV or high flow
7	Intubation and mechanical ventilation, $pO_2/FiO_2 > 150$ or $SpO_2/FiO_2 > 200$
8	Mechanical ventilation, $pO_2/FiO_2 < 150$ ($SpO_2/FiO_2 < 200$) or vasopressors
9	Mechanical ventilation $pO_2/FiO_2 < 150$ and vasopressors, dialysis, or ECMO
10	Dead